Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microneedling RF + Salicylic Acid for Refractory Rosacea
NCT06969300Completed
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Salvax in rosacea (2 arms), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: The range, quantity and degree of facial erythema at 12 weeks, Erythema score at 12 weeks and 5 more. Started Dec 2023; status: completed.
02
Drugs
Salvax
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT06969300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06969300.